AGP Executive Report
Last update: 9 hours agoSwiss Pharma & Biotech: Sandoz laid out a “golden decade” push to more than double annual net sales by 2035, with biosimilars as the growth engine. Clinical Setback: Novartis shares slid after a late-stage del-desiran trial missed its main goal in myotonic dystrophy type 1, adding pressure to its pipeline. Aviation & MRO: Pratt & Whitney’s PW4000 is seeing more shop visits than expected, prompting Swiss MRO SR Technics to expand capacity and training. Swiss Defense Aviation: Pilatus’ PC-7 MKX completed its first flight in Stans, with NATO air forces already committed and deliveries to the Netherlands planned from May 2027. Energy & Markets: Oil hovered near $100 as Middle East tensions and attacks on Saudi infrastructure stoked inflation fears; Swiss equities were hit by heavy Novartis weakness. Swiss Finance & Crypto: SIX and TWINT joined a CHF stablecoin sandbox as legal frameworks lag, while SIX also expanded SME trading activity. Swiss Industry Automation: ABB’s Machine Automation division (B&R) eyes Penang as a Southeast Asia operations hub, citing life sciences, medical devices and semiconductors demand. Food & Agriculture: Feast Farm in Montpelier (city-run) is back to growing after flood damage, using no-till and volunteer support to supply local food-insecurity programs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
